Blog

Philippine Manufacturing Co. of Murata, Inc. (Batangas, Philippines), a manufacturing subsidiary of Murata Manufacturing Co., Ltd., has completed a new production building that had been under construction since August 2023, and a ceremony to celebrate its completion was held on Wednesday, October 22. The completion of the new building strengthens our global production capabilities as we respond to the medium to long term increase in demand for multilayer ceramic capacitors (MLCCs) driven by the expected future growth of the mobility market.

Scene from the completion ceremony (October 22, 2025)

Overview of the completion ceremony

Overview of the new production building

Philippine Manufacturing Co. of Murata, Inc.

We are building a framework that enables us to respond flexibly to market changes and demand growth by distributing MLCC production bases across Japan, ASEAN, and China to ensure balanced capacity expansion. Below is the schedule for the construction of MLCC-related buildings that were completed, or are planned to be completed, in 2023 and thereafter.

GSK plc (LSE/NYSE: GSK) today announced positive phase III data from its clinical programme to develop a next-generation version of its metered dose inhaler (MDI), Ventolin (salbutamol). Data confirm that the formulation of salbutamol MDI containing an innovative low carbon propellant HFA-152a shows therapeutic equivalence and is comparable in safety to salbutamol MDI containing the current propellant, HFA-134a.

The findings will support regulatory submissions for the next-generation version, with launch expected from 2026, an important advance to bringing a more sustainable option to patients with respiratory disease.

Nearly half a billion people are affected by asthma and chronic obstructive pulmonary disease (COPD) around the world⁴ and approximately 300 million salbutamol MDIs are sold globally every year^1,2. Used during an exacerbation, or “attack”, salbutamol in an MDI can help by immediately treating a sudden onset of respiratory symptoms, such as breathlessness.

Kaivan Khavandi, SVP, Global Head, Respiratory, Immunology & Inflammation R&D, GSK, said: “Healthy air is essential for healthy lungs, and our next-generation salbutamol has the potential to reduce greenhouse gas emissions by 92%³ per inhaler. Almost six decades after its first development, this medicine remains highly valued by patients and healthcare professionals and is a key component of our respiratory portfolio. Today, we are one step closer to a reliever MDI that we believe will continue to help patients for many decades to come.”

Due to the scale of volume and worldwide use, GSK’s salbutamol MDI currently accounts for close to half (45%)⁵ of the company’s total global carbon footprint. GSK has partnered to use cutting-edge propellant technologies to develop a next-generation low-carbon version and has added advanced manufacturing technologies to support launch of this inhaler.

Prof. Ashley Woodcock, Professor of Respiratory Medicine at the University of Manchester, said: “While low carbon alternatives already exist, such as dry powder and soft mist inhalers, we know that many patients worldwide with both asthma and COPD prefer a salbutamol MDI to relieve their symptoms. These data should enable patients to use their preferred inhaler choice. This is a crucial advance to help global healthcare systems meet their climate targets at the same time as optimising the care of patients.”

About inhaled medicines

Inhaled medicines are administered to the lungs using an inhaler device. There are two main types of devices, metered dose inhalers (MDIs) and dry power inhalers (DPIs). All MDIs use a propellant to administer the medicine from the inhaler into the patient’s lungs. DPIs are propellant free, as the medicine is administered by the patients breathing in the powder, and therefore have a lower carbon impact compared to MDIs still using high global warming potential (GWP) propellants.

Eurostar is to start running doubledecker trains through the Channel tunnel to meet growing demand for international rail travel from the UK.

The rail operator announced it had signed a €2bn (£1.7bn) deal for at least 30 – and up to 50 – new trains from the manufacturer Alstom.

The doubledeckers will start operating from 2031, with each able to carry more than 1,000 passengers.

Eurostar said the Celestia trains, the first doubledeckers to run on the UK mainland, would have about 20% more seats than its biggest existing trains. Some of the extra space would be taken up by stairs, but it would also be used for wheelchairs, bicycles, additional legroom and “surprises”, it said.

The SNCF-owned operator plans to maintain the entire fleet at the Temple Mills depot in north-east London, which it hopes to redevelop with a further €80m investment, creating 350 jobs.

The announcement comes as the UK regulator, the Office of Rail and Road, is preparing to announce a critical decision on whether Eurostar should make space at Temple Mills for a competitor.

A number of other interested international high-speed rail operators, including Virgin, FS Italiane (Trenitalia, partnering with Spanish firm Evolyn) and Gemini have bid for the depot space, which Eurostar says is not feasible given its own expansion plans.

Last week, FS Italiane pledged its cross-Channel services would call at Ashford, Kent if successful, after ministers urged the ORR to favour bids that reopened disused UK high-speed stations.

Eurostar’s chief executive, Gwendoline Cazenave, said the timing of its train order announcement was a coincidence, as it continued to bounce back to growth after years of decline.

She said: “Placing this milestone order marks the concrete realisation of Eurostar’s ambitious growth strategy: to reach 30 million passengers by investing in a brand-new fleet. We’re particularly proud to bring doubledecker trains to the UK for the very first time.

“Customers can expect a very special new train with Eurostar Celestia, which will offer exceptional comfort, a unique Eurostar experience and new surprises to be revealed.”

The chief executive of manufacturer Alstom, Henri Poupart-Lafarge, said: “This new-generation train, designed to meet the demands of international very high-speed traffic, embodies our vision of sustainable and competitive European mobility.”

The trains will be able to operate throughout Eurostar’s network, including to its planned destinations of Frankfurt and Geneva. It will phase out its older trains, bar the 17 latest e320s, making its total fleet about 30% bigger once all 50 trains are delivered.

Cazenave said the order was long in the making, and Britain needed to increase its capacity for international rail, regardless of the imminent depot decision. She said: “Obviously, in the UK it’s a key milestone … but when I look at the demand, the way the market is pushing, what we are really pushing for is for the UK to find solutions for sustainable travel expansion between the UK and continent of Europe.

“You need private investment, as in the €2bn we’re putting on the table. But you also need a public transport policy, and investments in space. We need to find solutions for space for maintaining trains and we need also to find solutions for St Pancras,” the London passenger terminus.

Virgin has also signed a deal with Alstom, to buy 12 Avelia high-speed trains – a type currently in use in Italy and Sweden – should the regulator grant it depot space. The ORR is understood to have made a provisional decision at a board meeting on Tuesday, and is due to confirm it by 31 October.